Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

ClinicalTrials.gov ID: NCT00281593

Public ClinicalTrials.gov record NCT00281593. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study

Study identification

NCT ID
NCT00281593
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
1,354 participants

Conditions and interventions

Conditions

Interventions

  • Telmisartan Drug
  • Ramipril Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Mar 31, 2007
Completion
Not listed
Last update posted
Dec 27, 2017

Started 2006

United States locations

U.S. sites
70
U.S. states
28
U.S. cities
61
Facility City State ZIP Site status
1236.1.511 Boehringer Ingelheim Investigational Site Glendale Arizona
1236.1.574 Boehringer Ingelheim Investigational Site Tempe Arizona
1236.1.501 Boehringer Ingelheim Investigational Site Tucson Arizona
1236.1.557 Boehringer Ingelheim Investigational Site Tucson Arizona
1236.1.523 Boehringer Ingelheim Investigational Site Buena Park California
1236.1.514 Boehringer Ingelheim Investigational Site Concord California
1236.1.560 Boehringer Ingelheim Investigational Site Encinitas California
1236.1.573 Boehringer Ingelheim Investigational Site Long Beach California
1236.1.516 Boehringer Ingelheim Investigational Site Los Angeles California
1236.1.529 Boehringer Ingelheim Investigational Site Roseville California
1236.1.519 Boehringer Ingelheim Investigational Site Tustin California
1236.1.543 Boehringer Ingelheim Investigational Site Westlake Village California
1236.1.528 Boehringer Ingelheim Investigational Site Boulder Colorado
1236.1.530 Boehringer Ingelheim Investigational Site Farmington Connecticut
1236.1.572 Boehringer Ingelheim Investigational Site DeLand Florida
1236.1.577 Boehringer Ingelheim Investigational Site Hialeah Florida
1236.1.526 Boehringer Ingelheim Investigational Site Jupiter Florida
1236.1.527 Boehringer Ingelheim Investigational Site Largo Florida
1236.1.503 Anchor Research Center Naples Florida
1236.1.520 Boehringer Ingelheim Investigational Site New Port Richey Florida
1236.1.571 Boehringer Ingelheim Investigational Site Pembroke Pines Florida
1236.1.565 Boehringer Ingelheim Investigational Site Blue Ridge Georgia
1236.1.538 Boehringer Ingelheim Investigational Site Meridian Idaho
1236.1.532 Boehringer Ingelheim Investigational Site Peoria Illinois
1236.1.553 Boehringer Ingelheim Investigational Site Avon Indiana
1236.1.546 River Cities Cardiology Research Inst of Middle America Jeffersonville Indiana
1236.1.563 Boehringer Ingelheim Investigational Site Valparaiso Indiana
1236.1.517 Boehringer Ingelheim Investigational Site Newton Kansas
1236.1.531 Boehringer Ingelheim Investigational Site Wichita Kansas
1236.1.566 Boehringer Ingelheim Investigational Site Richmond Kentucky
1236.1.551 Boehringer Ingelheim Investigational Site Auburn Maine
1236.1.536 Boehringer Ingelheim Investigational Site Haverhill Massachusetts
1236.1.576 Boehringer Ingelheim Investigational Site North Dartmouth Massachusetts
1236.1.561 Clinical Research Center of Cape Cod West Yarmouth Massachusetts
1236.1.555 Boehringer Ingelheim Investigational Site Cadillac Michigan
1236.1.509 Boehringer Ingelheim Investigational Site Troy Michigan
1236.1.541 Boehringer Ingelheim Investigational Site Excelsior Springs Missouri
1236.1.556 Boehringer Ingelheim Investigational Site Las Vegas Nevada
1236.1.525 Physicians Research Center, LLC, Toms River Toms River New Jersey
1236.1.508 Boehringer Ingelheim Investigational Site Albuquerque New Mexico
1236.1.522 Boehringer Ingelheim Investigational Site Albuquerque New Mexico
1236.1.542 Boehringer Ingelheim Investigational Site Albuquerque New Mexico
1236.1.547 Boehringer Ingelheim Investigational Site Cincinnati Ohio
1236.1.567 Boehringer Ingelheim Investigational Site Columbus Ohio
1236.1.515 Boehringer Ingelheim Investigational Site Kettering Ohio
1236.1.575 Boehringer Ingelheim Investigational Site Tulsa Oklahoma
1236.1.554 Boehringer Ingelheim Investigational Site Corvallis Oregon
1236.1.524 Boehringer Ingelheim Investigational Site Eugene Oregon
1236.1.544 Boehringer Ingelheim Investigational Site Medford Oregon
1236.1.545 Boehringer Ingelheim Investigational Site Portland Oregon
1236.1.569 Boehringer Ingelheim Investigational Site Erie Pennsylvania
1236.1.505 Ledeeach Family Medicine Harleysville Pennsylvania
1236.1.564 Boehringer Ingelheim Investigational Site Tipton Pennsylvania
1236.1.534 Boehringer Ingelheim Investigational Site Cumberland Rhode Island
1236.1.539 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1236.1.568 Boehringer Ingelheim Investigational Site Carrollton Texas
1236.1.549 Boehringer Ingelheim Investigational Site Houston Texas
1236.1.559 Boehringer Ingelheim Investigational Site Houston Texas
1236.1.548 Boehringer Ingelheim Investigational Site San Antonio Texas
1236.1.550 Boehringer Ingelheim Investigational Site San Antonio Texas
1236.1.570 Boehringer Ingelheim Investigational Site The Colony Texas
1236.1.510 Boehringer Ingelheim Investigational Site Salt Lake City Utah
1236.1.513 Boehringer Ingelheim Investigational Site Salt Lake City Utah
1236.1.521 Boehringer Ingelheim Investigational Site Salt Lake City Utah
1236.1.512 Boehringer Ingelheim Investigational Site Sandy City Utah
1236.1.535 Boehringer Ingelheim Investigational Site Sandy City Utah
1236.1.502 Boehringer Ingelheim Investigational Site Falls Church Virginia
1236.1.504 Boehringer Ingelheim Investigational Site Madison Wisconsin
1236.1.540 Boehringer Ingelheim Investigational Site Madison Wisconsin
1236.1.562 Boehringer Ingelheim Investigational Site Menomonee Falls Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00281593, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 27, 2017 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00281593 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →